Kairos Pharma Ltd. (NYSE American: KAPA) announced it will host a key opinion leader event on September 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. The clinical-stage biopharmaceutical company focuses on developing innovative cancer therapeutics that address drug resistance and immune suppression in cancer treatment.
CEO Dr. John Yu stated that the event will highlight safety and efficacy findings from the ENV105 and apalutamide combination therapy. Expert perspectives during the presentation will underscore the compound's potential role in addressing cancer drug resistance, a significant challenge in modern oncology treatment. The company's approach utilizes structural biology to overcome treatment resistance mechanisms that often lead to disease relapse.
ENV105 represents a novel therapeutic approach as an antibody that specifically targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to the company's research, elevation of CD105 in response to standard therapy results in resistance and disease progression. The compound aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
The Phase 2 clinical trial focuses on castrate-resistant prostate cancer, while a separate Phase 1 trial is underway for lung cancer applications. Both trials address significant unmet medical needs in oncology, particularly the challenge of treatment resistance that often develops after initial therapy success. The upcoming presentation will provide valuable insights into the compound's performance and potential clinical benefits.
Investors and stakeholders can access additional information through the company's newsroom at https://ibn.fm/KAPA. The event represents an important milestone in cancer drug development, particularly for patients with advanced prostate cancer who have limited treatment options after developing resistance to standard therapies.
